Eurneffy (epinephrine)
- Region
- 🇪🇺 EU
- Active substance
- epinephrine
- Company
- ALK-Abelló A/S
- Status
- Authorised
- Therapeutic area
- Anaphylaxis
- CHMP opinion
- Thu 27 Jun 2024
- EU approval
- Thu 22 Aug 2024
- Application
- EMEA/H/C/006139
- ATC
- C01CA24
- Official record
- www.ema.europa.eu
Indication
Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over with a body weight of 15 kg or more.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇺🇸 Flavalta Approved · Deproco
- 🇪🇺 Neffy Application withdrawn · Ars Pharmaceuticals Irl Limited
- 🇺🇸 Epinephrine Approved · Baxter Hlthcare Corp
Follow Eurneffy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.